TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04283578

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OT
Description: One group will receive OT for 4 weeks, then placebo or OT for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.
Study: NCT04450498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yuxi Walvax MPV ACYW® vaccine
Description: Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects \> 2 years of age and have shown to be safe and immunogenic.
Study: NCT00793468

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK598809
Description: GSK598809 once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Transdermal Patch
Description: All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
Study: NCT04450498

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanofi Pasteur Menactra® vaccine
Description: The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.
Study: NCT04550468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Carb High-Fat breakfast
Description: Participants will receive 8 low-carb high-fat breakfast meal recipes to follow daily during 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat standard care control breakfast
Description: Participants will receive 8 low-fat breakfast meal recipes to follow daily during 3 months.
Study: NCT03898167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed HPV Self-Sampling Kit
Description: Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
Study: NCT00437086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341
Description: 1.6 mg/m2 by IV; 4 out of 5 weeks
Study: NCT00092456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rotavirus vaccine, live, oral, pentavalent
Description: Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rotavirus vaccine, live, oral, pentavalent
Description: Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rotavirus vaccine, live, oral, pentavalent
Description: Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
Study: NCT04218656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: 2.5 mg rivaroxaban twice a day in addition to Aspirin 100mg once a day (standard care).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: 2.5 mg rivaroxaban twice a day in addition to Aspirin 100mg once a day (standard care).
Study: NCT00158886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: For radiation therapy, subjects will receive 180 centigray (cGy) per fraction to a total dose of 4500 cGy to the pelvis using a 3 or 4 field technique and high energy photons (\>=6 megavolt \[mv\]).
Study: NCT03466684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIA-guided fluid resuscitation protocol
Description: In both groups, a multi-frequency BIA with eight tactile electrodes (Inbody S10 Biospace, Biospace Co. Ltd., Seoul, Korea) was used to assess body fluid status every 6h within the first 72h after admission to the ICU and daily for a period of 4 days.~BIA recording was not adjusted by clinicians in fluid restrict, pharmacological and mechanical means of therapy.~In contrast, in group BIA, fluid resuscitation protocol with adjustment determined according to HL measured by BIA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional fluid resuscitation protocol
Description: Traditional fluid resuscitation strategy determined by treating clinicians according to usual clinical parameters.
Study: NCT03693183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac/HPMC
Description: 0.30% Ketorolac/0.80%HPMC Ophthalmic solution administered 4 times per day for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPMC
Description: 0.80% Hydroxypropyl Methylcellulose solution 4 times per day for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study: NCT01707810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piggyback method
Description: In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: conventional method
Study: NCT01735825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel-coated balloon catheter with Iopromide coating
Description: Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting stent with everolimus
Description: Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus

Intervention type: DEVICE
Group type: OTHER
Intervention: seal-wing paclitaxel-eluting balloon catheter
Description: Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
Study: NCT00175149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidiol
Description: Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
Study: NCT01736644

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrocautery
Description: Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar sealer Aquamantys
Description: Aquamantys use in tourniquet and tourniquetless total knee replacement.
Study: NCT02648373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
Study: NCT04053881

Intervention type: DRUG
Intervention: Certolizumab pegol
Description: Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
Study: NCT00006170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: smoking cessation medication aid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: smoking cessation medication aid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A matched placebo pill
Study: NCT04462653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Dynamic ECG Recorder
Description: use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-lead ECG recordings
Description: use a 12-lead ECG recordings to record heart rate and atrial fibrillation
Study: NCT02827851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SVF isolation
Description: SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
Study: NCT00006170

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo pill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight concerns intervention
Description: cognitive behavioral treatment to address weight concners
Study: NCT00793468

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Transdermal Patch
Description: All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 weeks
Study: NCT00006170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight concerns intervention
Description: cognitive behavioral treatment to address weight concners
Study: NCT03534518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BWS overground training
Description: BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. The walking tasks will be roughly divided into different domains like skilled walking, balance, dual tasking, walking speed, walking endurance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BWS treadmill training
Description: Training will be conducted on a standard treadmill with an overhead BWS system that can provide active BWS. Participants are allowed to hold the rails but weight bearing is not allowed. BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. Main walking tasks will be endurance (walking long distances at preferred speed) and speed (walking at maximal possible speed).
Study: NCT01373502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DES Limus Carbostent
Description: DES Limus Carbostent Carbofilm Coated Coronary Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberté Stent
Description: Taxus Liberté Coronary Stent
Study: NCT00006170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation intervention
Description: Cognitive behavioral intervention for smoking cessation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation intervention
Description: Cognitive behavioral intervention for smoking cessation
Study: NCT01517724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
Study: NCT01816971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic stem cell transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03818490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bergamot Aromatherapy
Description: Patients in this group inhaled bergamot essential oil for 15 minutes.
Study: NCT03708328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomvastomig
Description: Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomvastomig
Description: Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomvastomig
Description: Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomvastomig
Description: Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomvastomig
Description: Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomvastomig
Description: Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
Study: NCT05020223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vital pulp therapy
Description: Vital pulp therapy different modalities for management of deep carious lesion in primary teeth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vital pulp therapy
Description: Vital pulp therapy different modalities for management of deep carious lesion in primary teeth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vital pulp therapy
Description: Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
Study: NCT01247129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delay procedure of SIEA flap.
Description: Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
Study: NCT04545008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral Famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine
Study: NCT00454558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
Study: NCT04545008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Oral N-Acetyl Cysteine
Study: NCT03557619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/levonorgestrel
Description: tablet; oral
Study: NCT01311271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~* Real: unaffected M1 hotspot~* Sham: coil perpendicular to scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~* Real: unaffected M1 hotspot~* Sham: coil perpendicular to scalp

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~* Real: unaffected M1 hotspot~* Sham: coil perpendicular to scalp
Study: NCT01004497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 \& 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 45 mg/m2/day, IV for 1 hour, days 4 \& 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg/day, IV push, days 1-4 \& days 11-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 12 mg/m2/day, IV for 30 minutes, days 1-2
Study: NCT04748562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Taking prontogest vaginally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Taking prontogest vaginally
Study: NCT04304430

Intervention type: DRUG
Intervention: Dapagliflozin
Description: Initiation of dapagliflozin according to clinical indication

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: Initiation of DPP-4i according to clinical indication
Study: NCT01453595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily
Study: NCT02098200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriCinch System
Description: Percutaneous treatment of Tricuspid Regurgitation
Study: NCT02047838

Intervention type: OTHER
Intervention: Anti-mullerian hormone (AMH) level dosage.

Intervention type: OTHER
Intervention: Anti-mullerian hormone (AMH) level dosage.

Intervention type: OTHER
Intervention: Follicle-stimulating hormone (FSH) level dosage.

Intervention type: OTHER
Intervention: Follicle-stimulating hormone (FSH) level dosage.

Intervention type: OTHER
Intervention: Antral follicle count (AFC).

Intervention type: OTHER
Intervention: Antral follicle count (AFC).